Trial Profile
Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Palifermin (Primary) ; Antithymocyte globulin; Cyclophosphamide; Degarelix; Leuprorelin; Thiotepa
- Indications Immunosuppression
- Focus Therapeutic Use
- 04 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 04 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 14 Apr 2021 Status changed from recruiting to active, no longer recruiting.